financingDutch NLC has €20m in first close of new...Dutch venture builder NLC has announced a €20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s targeting a final close … more ➔
financingFrench Carthera closes €37.5m Series B f...Carthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its €37.5m … more ➔
M&ADonaldson Acquires Belgian Univercells Tec...Donaldson Company, Inc. (NYSE: DCI), a heritage provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies (Belgium), a global provider of innovative … more ➔
financingGleamer raises €27m in Series B funding...French AI-powered radiography diagnostics specialist Gleamer SAS has raises €27m in Series B round to expand its portfolio and accelerate its expansion. more ➔
Joint ventureCentogene and Lifera kick-off joint ventur...Multi-omics diagnostics specialist Centogene NV has received €30m to form a joint venture with PIF-owned pharmaceutical company Lifera in Saudi-Arabia. more ➔
financingAstraveus SAS bags €16.5m in seed financ...French cell and gene therapy manufacturing specialist Astraveus SAS had raises €16.5m in seed money to advance its automated, microfluidic Cell and Gene Therapy manufacturing platform. more ➔
New BIOTECH insight newsletter outBreaking news from biotechnology and the German stock market are in the focus of the new issue of BIOTECH Insight, the newsletter of Deutsche Börse AG. more ➔
financingFresh money for Carbios Carbios SAS has announced a capital increase of around €122m that may grow up to €141m. more ➔
DigitisationSmarter, faster, cheaper: Veeva shows how This year’s Veeva R&D and Quality Summit in Madrid, accentuated the current trends and needs of the pharma and life sciences industries. more ➔
partnershipSanthera licences vamorolone rights to Cat... Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc. more ➔
